



Government & Cartel Investigations

Antitrust Life Sciences and Healthcare Capabilities

Overview

Baker Botts' Antitrust and Competition Law lawyers have extensive experience guiding life sciences and healthcare companies through the challenges of criminal and administrative cartel investigations, investigations into unilateral conduct and government investigations into other types of potentially anticompetitive conduct, while helping to minimize impacts on the company and its executive team. Our lawyers have handled cartel investigations in jurisdictions around the world, and our clients come to us when the very core of their business is at risk.

We are recognized as one of the world's leading competition practices. We have a thorough understanding of our clients' products and business models in the life sciences and healthcare sector along with deep experience with the applicable statutes and rules and the agencies and individuals that enforce them. Our lawyers know how to cooperate with enforcers around the world while understanding and advocating on behalf of our client's best interests.

Representative Experience

Our Antitrust and Competition Law group handles leading-edge matters for life sciences and healthcare companies on U.S., European, and international competition issues, including cartel investigations and defense of cartel prosecutions, cartel damage litigation, private antitrust litigation and defenses of clients in actions before government authorities, including investigations into predatory and excessive pricing, abusive use of intellectual property rights and misuse of governmental procedures in the pharmaceutical sector. Some of our investigations highlights include:

- **Eli Lilly** in antitrust investigations and litigation involving allegations of anticompetitive pricing.
- A **pharmacy benefit management firm** in connection with the FTC's investigation of a US\$12 billion horizontal merger.
- A **major pharmaceutical supplier** in its defense against an investigation by the European Commission into alleged collusive behavior and abuse of regulatory procedures.
- **Healthcare trade associations** in connection with federal antitrust investigations.
- **Fortune 200 company** in a non-public investigation by the DOJ into whether the client's participation with its competitors in an industry-wide trade association effort to promulgate detailed standard-setting for a next-generation ubiquitous consumer product constituted a conspiracy to boycott emerging technologies.

Austin Brussels Dallas Dubai Houston London
New York Palo Alto Riyadh San Francisco Singapore Washington

bakerbotts.com | Confidential | Copyright© 2023 Baker Botts L.L.P.

BAKER BOTTS 

- **Large branded pharmaceutical company** in the defense of multiple antitrust investigations by authorities in Brazil, South Africa, Israel, Korea, Italy, and India.
- **Major pharmaceutical company executive** in connection with DOJ/Antitrust Division investigation of suspected price signaling in the market for blood bank reagents.
- **Fortune 500 medical supply company** in a criminal investigation by U.S. Attorney's Office relating to sales of restricted pharmaceutical products.
- **Taro Pharmaceutical Industries Ltd.**, acting as co-lead counsel representing the company in connection with the DOJ criminal cartel investigation into the U.S. generic pharmaceutical industry.

Key Contacts

To learn more about our government and cartel investigations experience, please contact one of the lawyers below.



Mark J. Botti

Partner

T: +1.202.639.1116

mark.botti@bakerbotts.com



Paul Lugard

Partner

T: +32.2.891.7320

paul.lugard@bakerbotts.com